Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug;10(4):206-14.
doi: 10.1049/iet-nbt.2015.0056.

Luteinizing hormone-releasing hormone targeted poly(methyl vinyl ether maleic acid) nanoparticles for doxorubicin delivery to MCF-7 breast cancer cells

Jaleh Varshosaz  1 , Ali Jahanian-Najafabadi  2 , Jila Ghazzavi  3
Affiliations

Luteinizing hormone-releasing hormone targeted poly(methyl vinyl ether maleic acid) nanoparticles for doxorubicin delivery to MCF-7 breast cancer cells

Jaleh Varshosaz et al. IET Nanobiotechnol. 2016 Aug.

Abstract

The purpose of this study was to design a targeted anti-cancer drug delivery system for breast cancer. Therefore, doxorubicin (DOX) loaded poly(methyl vinyl ether maleic acid) nanoparticles (NPs) were prepared by ionic cross-linking method using Zn(2+) ions. To optimise the effect of DOX/polymer ratio, Zn/polymer ratio, and stirrer rate a full factorial design was used and their effects on particle size, zeta potential, loading efficiency (LE, %), and release efficiency in 72 h (RE72, %) were studied. Targeted NPs were prepared by chemical coating of tiptorelin/polyallylamin conjugate on the surface of NPs by using 1-ethyl-3-(3-dimethylaminopropyl) carboiimid HCl as cross-linking agent. Conjugation efficiency was measured by Bradford assay. Conjugated triptorelin and targeted NPs were studied by Fourier-transform infrared spectroscopy (FTIR). The cytotoxicity of DOX loaded in targeted NPs and non-targeted ones were studied on MCF-7 cells which overexpress luteinizing hormone-releasing hormone (LHRH) receptors and SKOV3 cells as negative LHRH receptors using Thiazolyl blue tetrazolium bromide assay. The best results obtained from NPs prepared by DOX/polymer ratio of 5%, Zn/polymer ratio of 50%, and stirrer rate of 960 rpm. FTIR spectrum confirmed successful conjugation of triptorelin to NPs. The conjugation efficiency was about 70%. The targeted NPs showed significantly less IC50 for MCF-7 cells compared to free DOX and non-targeted NPs.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Contribution of different effective factors on the particle size, zeta potential, drug loading efficiency (LE %), drug release after 72 h (RE72 %)
Fig. 2
Fig. 2
Effect of different levels of studied parameters on the particle size, zeta potential, loading efficiency and drug release efficiency of DOX loaded PMVEMA NPs
Fig. 3
Fig. 3
DOX release profile from different studied PMVEMA NPs
Fig. 4
Fig. 4
FTIR spectrum of a Triptorelin b Polyallylamine c Conjugated triptorelin/polyallylamine
Fig. 5
Fig. 5
FTIR spectrum of a Non‐targeted b Targeted NPs
Fig. 6
Fig. 6
TEM micrographs of optimized formulation of doxorubicin loaded NPs
Fig. 7
Fig. 7
Viability of a MCF‐7 b SKOV3 cells after treatment with different concentrations of targeted and non‐targeted NPs with or without DOX compared to free DOX by MTT assay
See this image and copyright information in PMC

References

    1. American Cancer Society : ‘Breast cancer facts and figures 2011–2012’ (American Cancer Society, Atlanta, Ga, USA, 2012)
    1. Greenlee R.T. Murray T. Bolden S. et al.: ‘Cancer statistics’, CA Cancer J. Clin., 2000, 50, pp. 7 –33 (doi: 10.3322/canjclin.50.1.7) - DOI - PubMed
    1. Wang X. Teng Z. Wang H.: ‘Increasing the cytotoxicity of DOX in breast cancer MCF‐7 cells with multidrug resistance using a mesoporous silica nanoparticle drug delivery system’, Int. J. Clin. Exp. Pathol., 2014, 7, (4), pp. 1337 –1347 - PMC - PubMed
    1. Jones K.L.: ‘Breast cancer’, in Alldrege B.K. Corelli R.L. Ernst M.E. (Eds.): ‘Koda‐Kimble and Young's Applied Thrapeutics, the clinical use of Drugs’ (Lippincott Williams and Wilkins, New York, 2012, 10th edn.), pp. 2129 –2199
    1. Brannon‐Peppas L. Blanchette O.J.: ‘Nanoparticle and targeted system for cancer therapy’, Adv. Drug Deliv. Rev., 2012, 64, pp. 206 –212 (doi: 10.1016/j.addr.2012.09.033) - DOI - PubMed

MeSH terms

LinkOut - more resources